<DOC>
	<DOCNO>NCT01214122</DOCNO>
	<brief_summary>The primary purpose study determine whether treatment AZD9668 affect metabolism effect Warfarin .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Between AZD9668 Warfarin Study Effect AZD9668 Metabolism Effect Warfarin</brief_title>
	<detailed_description />
	<mesh_term>Warfarin</mesh_term>
	<criteria>Provision sign informed consent ( include genotyping screen sample CYP2C9 VKORC1 ) prior study specific procedure Subjects must willing use barrier method contraception , unless partner postmenopausal surgically sterile , female partner childbearing potential subject must use barrier method contraception ( condom ) partner must use accepted contraceptive method ( oral contraceptive , implant , long term injectable contraceptive intrauterine device ) , first dose IP ( warfarin AZD9668 ) 3 month last dose IP ( warfarin AZD9668 ) Have body mass index 19 30 kg/m2 ( inclusive ) weight 50 100 kg ( inclusive ) Be nonsmoker exsmoker stop smoke &gt; 6 month prior Visit 1 . Any clinically significant disease disorder Subject predict high sensitivity warfarin base CYP2C9 VKORC1 genotypes Any clinically relevant abnormal finding physical examination</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Drug-Drug interaction</keyword>
	<keyword>warfarin</keyword>
	<keyword>AZD9668</keyword>
	<keyword>result AZD9668 Warfarin interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>